Darolutamide plus androgen-deprivation therapy (ADT) in patients with high-risk biochemical recurrence (BCR) of prostate cancer: A phase III, randomized, double-blind, placebo-controlled study (ARASTEP)

被引：1

作者：

Morgans, A. K. ^{[1
]}

Gschwend, J. E. ^{[2
]}

Shore, N. D. ^{[3
]}

Ross, A. ^{[4
]}

Feng, F. ^{[5
]}

Hope, T. ^{[6
]}

Trandafir, L. ^{[7
]}

Le Berre, M-A. ^{[8
]}

Kuss, I. ^{[9
]}

Joensuu, H. ^{[10
]}

Fizazi, K. ^{[11
]}

机构：

[1] Dana Farber Canc Inst, Med Dept, Boston, MA USA

[2] Tech Univ Munich, Dept Urol, Klinikum Rechts Isar, Munich, Germany

[3] GenesisCare US, Uro Oncol Dept, Carolina Urol Res Ctr, Myrtle Beach, SC USA

[4] Northwestern Univ, Urol, Feinberg Sch Med, Chicago, IL USA

[5] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, Radiat Oncol, San Francisco, CA USA

[6] Univ Calif San Francisco, Radiol Sch Med, San Francisco, CA USA

[7] Bayer Consumer Care AG, R&D Dept, Basel, Switzerland

[8] Bayer Healthcare France, Biometry, Loos, France

[9] Bayer AG, Clin Dev SBU Oncol, Berlin, Germany

[10] Orion Corp, Orion Pharma, Espoo, Finland

[11] Univ Paris Saclay, Dept Canc Med, Gustave Roussy, Villejuif, France

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.2789

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

184TiP

引用

页码：S997 / S998

页数：2

共 50 条

[41] LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer.
Fizazi, Karim
Namphuong Tran
Enrique Fein, Luis
Matsubara, Nobuaki
Rodriguez Antolin, Alfredo
Alekseev, Boris Y.
Ozguroglu, Mustafa
Ye, Dingwei
Feyerabend, Susan
Protheroe, Andrew
De Porre, Peter
Kheoh, Thian
Park, Youn C.
Todd, Mary Beth
Chi, Kim N.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (18)
[42] Metformin to treat prostate cancer (PCa) and prevent metabolic syndrome associated with androgen deprivation therapy (ADT): Results of a randomized double-blind placebo-controlled study of metformin in non-diabetic men initiating ADT for advanced PCa.
Mahalingam, Devalingam
Salih, Hanni
Fountzilas, Christos
Michalek, Joel
Sarantopoulos, John
Datta, Paromita
Romero, Ofelia
Pillai, Sureshkumar Mulampurath Achutan
Kuhn, John G.
Pollak, Michael N.
Thompson, Ian Murchie
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[43] A phase Ib/III randomized, double-blind, placebo-controlled study of tazemetostat plus doxorubicin as frontline therapy for patients with advanced epithelioid sarcoma.
Sen, Shiraj
McKean, Meredith Ann
Sierra, Laura
Ainscough, Jessica
Yang, Jay
Hamlett, Anthony
Zimmerman, Tom
Merchant, Melinda
Chawla, Sant P.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[44] Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial
Saad, Fred
Vjaters, Egils
Shore, Neal
Olmos, David
Xing, Nianzeng
Pereira de Santana Gomes, Andrea Juliana
Cesar de Andrade Mota, Augusto
Salman, Pamela
Jievaltas, Mindaugas
Ulys, Albertas
Jakubovskis, Maris
Kopyltsov, Evgeny
Han, Weiqing
Nevalaita, Liina
Testa, Isabella
Le Berre, Marie-Aude
Kuss, Iris
Haresh, Kunhi Parambath
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (36)
[45] Tadalafil therapy in pulmonary arterial hypertension: results of a randomized, double-blind, placebo-controlled, phase III study
Galie, N.
Brundage, B. H.
Ghofrani, A.
Oudiz, R. J.
Simonneau, G.
Beardsworth, A.
Chan, M.
Barst, R. J.
EUROPEAN HEART JOURNAL, 2008, 29 : 519 - 519
[46] Open-label study of darolutamide plus androgen-deprivation therapy (ADT) vs ADT in metastatic hormone-sensitive prostate cancer using an external control arm (ARASEC)
Shore, Neal D.
Ross, Ashley
Preston, Mark A.
Gregg, Justin R.
Salami, Simpa Samuel
Bruno, Amanda
Srinivasan, Shankar
Constantinovici, Niculae
Ortiz, Jorge A.
Littleton, Natasha
Verholen, Frank
McKay, Rana R.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[47] Preoperative Androgen Deprivation Therapy for Localized Prostate Cancer: Delayed Biochemical Recurrence in High-Risk Disease
Pal, Sumanta K.
Ruel, Nora
Vogelzang, Nicholas
Chang, Mark
Wilson, Timothy G.
Jones, Jeremy O.
Yuh, Bertram
CLINICAL GENITOURINARY CANCER, 2014, 12 (03) : 149 - 154
[48] Randomized, double-blind, placebo-controlled phase II trial of nanocurcumin in prostate cancer patients undergoing radiotherapy
Saadipoor, Afshin
Razzaghdoust, Abolfazl
Simforoosh, Nasser
Mahdavi, Arash
Bakhshandeh, Mohsen
Moghadam, Maryam
Abdollahi, Hamid
Mofid, Bahram
PHYTOTHERAPY RESEARCH, 2019, 33 (02) : 370 - 378
[49] Phase I study of concurrent weekly docetaxel, high-dose intensity-modulated radiation therapy (IMRT) and androgen-deprivation therapy (ADT) for high-risk prostate cancer
Chen, Ronald C.
Rosenman, Julian G.
Hoffman, Leroy G.
Chiu, Wing-Keung
Wang, Andrew Z.
Pruthi, Raj S.
Wallen, Eric M.
Crane, Jeffrey M.
Kim, William Y.
Rathmell, W. Kimryn
Godley, Paul A.
Whang, Young E.
BJU INTERNATIONAL, 2012, 110 (11B) : E721 - E726
[50] A randomized, double-blind, placebo-controlled phase III trial of duloxetine in Japanese fibromyalgia patients
Masato Murakami
Kenichi Osada
Hiromichi Mizuno
Toshimitsu Ochiai
Levent Alev
Kusuki Nishioka
Arthritis Research & Therapy, 17

← 1 2 3 4 5 →